Phosphoproteomics Startup Focuses on Cell-Signaling Pathways, Signs Deal with GSK

The company, called Activiomics, last week announced a collaboration with GlaxoSmithKline that will use its TIQUAS technology to analyze novel inflammatory pathways by identifying biomarkers and validating targets.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.